Quanli Gao
Zhengzhou University(CN)Henan Cancer Hospital(CN)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Lymphoma Diagnosis and Treatment, Immunotherapy and Immune Responses
Most-Cited Works
- → Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study(2019)153 cited
- → The Application of Nanobody in CAR-T Therapy(2021)107 cited
- → Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant(2020)80 cited
- → TGF-β blockade-improved chemo-immunotherapy with pH/ROS cascade-responsive micelle via tumor microenvironment remodeling(2021)52 cited
- → Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma(2021)51 cited
- → The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.(2019)31 cited
- → Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients(2022)19 cited
- → Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies(2021)9 cited
- → The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.(2021)9 cited
- → S-15 in combination of Akt inhibitor promotes the expansion of CD45RA−CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells(2019)7 cited